Analyst Viewpoint
Supportive therapeutic guidelines worldwide are fostering cancer cachexia market development. Rise in research in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) coupled with growth in awareness regarding the benefits of NSAIDs among the patient population is also boosting market progress.
Cancer cachexia market insights reveal that nutritional supplements are not enough by themselves to arrest or manage the wasting of body muscles due to the disease. This has necessitated aggressive research in treatment modalities - many pipeline drugs are currently under clinical trials. Governments are also playing a key role in market expansion by establishing specialized channels for dissemination of information to the general public.
Cancer cachexia is characterized by anorexia, skeletal muscle atrophy, and metabolic abnormalities inside the body. Implementation of a thorough and well-rounded therapeutic approach can help arrest or avoid muscular atrophy and weight loss in cancer-afflicted patients.
In its most extreme form, cachexia's physical decline can leave a person not just weak and exhausted, but also unable or reluctant to eat and with significant changes in appearance.
Emerging treatments for cancer cachexia should include not just pharmaceutical therapy but also a variety of measures such as dietary therapy, exercise, and psychological interventions. Research is being conducted in pharmacological medicines comprising varying substances. Advances reveal that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are showing promising results. Further usage of novel agents in clinical studies is underway, and they are likely to hit the market shortly.
According to the U.S. National Institute of Health (NIH), cancer cachexia is estimated to affect up to 80% of persons with advanced cancer. It is likely to be the direct cause of up to 30% of cancer fatalities, often due to cardiac or respiratory failure caused by muscle loss.
Clinical trials in oncology reveal the multifactorial pathogenicity of cancer cachexia. These studies indicate the suitability of progestogens as the preferred and most accessible treatment for cancer-related cachexia globally. Cancer cachexia market analysis highlights the rise in popularity of progestogens as the therapy of choice for the disease in Europe.
Guidance on diet and exercise co-therapy is required in the context of a complicated illness process. There is unanimous recognition in the medical community that this may entail further clinical studies for food items and supportive care measures.
Companies also report higher convenience in drug and compound testing for cancer cachexia with clearly structured regulatory guidelines. Regulators are encouraging extensive testing of such modalities and their progressive inclusion in treatment procedures by designing innovative trial processes.
Exercise rehabilitation is well established in the subject of COPD-associated body atrophy, with comprehensive evidence-based guideline recommendations. These recommendations have evolved over the years and utilize multiple treatment modalities that have emerged as key factors influencing cancer cachexia market dynamics.
They specifically aim to enhance physical functioning and activity levels, nutritional retention, and quality of life. Novel drugs for cancer related cachexia are primarily focused on specific elements of the illness (e.g., muscular anabolism, inflammation, or appetite stimulation).
Clinical care of cancer cachexia is difficult due to its complex pathophysiology, and there are currently no proven therapies. Corticosteroids and progestins are often administered, but their usage is limited due to serious side effects. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are being studied for cancer cachexia.
According to the British National Formulary (BNF), therapeutic benefits include both analgesic and anti-inflammatory action, with roughly 60% of patients responding to an NSAID. NSAIDs inhibit the cyclooxygenase (COX)/prostaglandin pathway, which is important in the control of the inflammatory response.
Non-selective NSAIDs (such as Ibuprofen) inhibit both COX1 and COX2, whereas selective NSAIDs (such as Celecoxib) exclusively inhibit COX2. NSAIDs have been advocated as therapeutic possibilities for cancer cachexia since inflammation has largely been identified as a significant factor in the development of cancer cachexia. This is in addition to their overall safety of usage in the general population. Thus, rise in research regarding NSAIDs is a prominent factor that is augmenting cancer cachexia market growth.
The cancer cachexia market report scope includes regional segmentation, which reveals that North America dominated the industry in 2022. Rise in awareness programs related to cancer care is fueling market growth in the region.
Increase in number of pipeline drugs in stage three clinical trials is also expected to drive the cancer cachexia market share of North America. These drugs are likely to hit the market in the next few years.
Asia Pacific is projected to record significant market development during the forecast period. This can be ascribed to the presence of a large pool of undiagnosed patients and rapid migration of the populace to urban settlements for advanced medical care.
Increase in disposable income has, in general, is also improving patient access to novel therapies for cancer cachexia. Rise in government support for healthcare infrastructure and increase in awareness regarding the disease are further anticipated to positively influence market statistics.
The global cancer cachexia market is highly fragmented, with the presence of large numbers of companies. Key market players are investing significantly in research and development activities.
Prominent manufacturers of cancer cachexia drugs are Aeterna Zentaris, Inc., Alder BioPharmaceuticals Inc., Aphios Corporation, Eli Lilly and Company, GTx Inc., Helsinn Group, Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, and XBiotech, Inc. Many of these players are entering into collaborations to expand their footprint across the globe.
These companies have been summarized in the cancer cachexia market report based on parameters such as company overview, financial overview, business strategies, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 2.2 Bn |
| Market Forecast Value in 2031 | US$ 3.6 Bn |
| Growth Rate (CAGR) | 4.7% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 2.2 Bn in 2022
It is likely to grow at a CAGR of 4.7% from 2023 to 2031
Supportive therapeutic guidelines worldwide and rise in research in Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
North America was the leading region in 2022
Aeterna Zentaris, Inc., Alder BioPharmaceuticals Inc., Aphios Corporation, Eli Lilly and Company, GTx Inc., Helsinn Group, Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, and XBiotech, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Cachexia Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Cachexia Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Cancer Cachexia Market Analysis and Forecast, by Therapeutics
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapeutics, 2023–2031
6.3.1. Progestogens
6.3.2. Corticosteroids
6.3.3. Combination Therapies
6.3.4. Others
6.4. Market Attractiveness Analysis, by Therapeutics
7. Global Cancer Cachexia Market Analysis and Forecast, by Mechanism of Action
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Mechanism of Action, 2023–2031
7.3.1. Appetite Stimulators
7.3.2. Weight Loss Stabilizers
7.3.3. Others
7.4. Market Attractiveness Analysis, by Mechanism of Action
8. Global Cancer Cachexia Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2023–2031
8.3.1. Hospital Stores
8.3.2. Retail Pharmacy Stores
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Mechanism of Action
9. Global Cancer Cachexia Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cancer Cachexia Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Therapeutics, 2023–2031
10.3.1. Progestogens
10.3.2. Corticosteroids
10.3.3. Combination Therapies
10.3.4. Others
10.4. Market Value Forecast, by Mechanism of Action, 2023–2031
10.4.1. Appetite Stimulators
10.4.2. Weight Loss Stabilizers
10.4.3. Others
10.5. Market Value Forecast, by Distribution Channel, 2023–2031
10.5.1. Hospital Stores
10.5.2. Retail Pharmacy Stores
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2023–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Therapeutics
10.7.2. By Mechanism of Action
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Cancer Cachexia Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Therapeutics, 2023–2031
11.3.1. Progestogens
11.3.2. Corticosteroids
11.3.3. Combination Therapies
11.3.4. Others
11.4. Market Value Forecast, by Mechanism of Action, 2023–2031
11.4.1. Appetite Stimulators
11.4.2. Weight Loss Stabilizers
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2023–2031
11.5.1. Hospital Stores
11.5.2. Retail Pharmacy Stores
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2023–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Therapeutics
11.7.2. By Mechanism of Action
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Cancer Cachexia Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Therapeutics, 2023–2031
12.3.1. Progestogens
12.3.2. Corticosteroids
12.3.3. Combination Therapies
12.3.4. Others
12.4. Market Value Forecast, by Mechanism of Action, 2023–2031
12.4.1. Appetite Stimulators
12.4.2. Weight Loss Stabilizers
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2023–2031
12.5.1. Hospital Stores
12.5.2. Retail Pharmacy Stores
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2023–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Therapeutics
12.7.2. By Mechanism of Action
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Cancer Cachexia Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Therapeutics, 2023–2031
13.3.1. Progestogens
13.3.2. Corticosteroids
13.3.3. Combination Therapies
13.3.4. Others
13.4. Market Value Forecast, by Mechanism of Action, 2023–2031
13.4.1. Appetite Stimulators
13.4.2. Weight Loss Stabilizers
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2023–2031
13.5.1. Hospital Stores
13.5.2. Retail Pharmacy Stores
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2023–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Therapeutics
13.7.2. By Mechanism of Action
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Cancer Cachexia Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Therapeutics, 2023–2031
14.3.1. Progestogens
14.3.2. Corticosteroids
14.3.3. Combination Therapies
14.3.4. Others
14.4. Market Value Forecast, by Mechanism of Action, 2023–2031
14.4.1. Appetite Stimulators
14.4.2. Weight Loss Stabilizers
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2023–2031
14.5.1. Hospital Stores
14.5.2. Retail Pharmacy Stores
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2023–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Therapeutics
14.7.2. By Mechanism of Action
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Aeterna Zentaris, Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Alder BioPharmaceuticals Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Aphios Corporation
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Eli Lilly and Company
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. GTx Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Helsinn Group
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Merck & Co. Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Novartis AG
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Bristol-Myers Squibb Company
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. XBiotech, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Cancer Cachexia Market Size (US$ Bn) Forecast, by Therapeutics, 2023–2031
Table 02: Global Cancer Cachexia Market Size (US$ Bn) Forecast, by Mechanism of Action, 2023–2031
Table 03: Global Cancer Cachexia Market Size (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 04: Global Cancer Cachexia Market Size (US$ Bn) Forecast, by Region, 2023–2031
Table 05: North America Cancer Cachexia Market Size (US$ Bn) Forecast, by Country, 2023–2031
Table 06: North America Cancer Cachexia Market Size (US$ Bn) Forecast, by Therapeutics, 2023–2031
Table 07: North America Cancer Cachexia Market Size (US$ Bn) Forecast, by Mechanism of Action, 2023–2031
Table 08: North America Cancer Cachexia Market Size (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 09: Europe Cancer Cachexia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 10: Europe Cancer Cachexia Market Size (US$ Bn) Forecast, by Therapeutics, 2023–2031
Table 11: Europe Cancer Cachexia Market Size (US$ Bn) Forecast, by Mechanism of Action, 2023–2031
Table 12: Europe Cancer Cachexia Market Size (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 13: Asia Pacific Cancer Cachexia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Asia Pacific Cancer Cachexia Market Size (US$ Bn) Forecast, by Therapeutics, 2023–2031
Table 15: Asia Pacific Cancer Cachexia Market Size (US$ Bn) Forecast, by Mechanism of Action, 2023–2031
Table 16: Asia Pacific Cancer Cachexia Market Size (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 17: Latin America Cancer Cachexia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 18: Latin America Cancer Cachexia Market Size (US$ Bn) Forecast, by Therapeutics, 2023–2031
Table 19: Latin America Cancer Cachexia Market Size (US$ Bn) Forecast, by Mechanism of Action, 2023–2031
Table 20: Latin America Cancer Cachexia Market Size (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 21: Middle East & Africa Cancer Cachexia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 22: Middle East & Africa Cancer Cachexia Market Size (US$ Bn) Forecast, by Therapeutics, 2023–2031
Table 23: Middle East & Africa Cancer Cachexia Market Size (US$ Bn) Forecast, by Mechanism of Action, 2023–2031
Table 24: Middle East & Africa Cancer Cachexia Market Size (US$ Bn) Forecast, by Distribution Channel, 2023–2031
List of Figures
Figure 01: Global Cancer Cachexia Market Size (US$ Bn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Cancer Cachexia Market Revenue (US$ Bn), by Therapeutics, 2022
Figure 03: Global Cancer Cachexia Market Value Share, by Therapeutics, 2022
Figure 04: Global Cancer Cachexia Market Revenue (US$ Bn), by Mechanism of Action, 2022
Figure 05: Global Cancer Cachexia Market Value Share, by Mechanism of Action, 2022
Figure 06: Global Cancer Cachexia Market Revenue (US$ Bn), by Distribution Channel, 2022
Figure 07: Global Cancer Cachexia Market Value Share, by Distribution Channel, 2022
Figure 08: Global Cancer Cachexia Market Value Share, by Region, 2022
Figure 09: Global Cancer Cachexia Market Value (US$ Bn) Forecast, 2023–2031
Figure 10: Global Cancer Cachexia Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 11: Global Cancer Cachexia Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 12: Global Cancer Cachexia Market Value Share Analysis, by Mechanism of Action, 2022 and 2031
Figure 13: Global Cancer Cachexia Market Attractiveness Analysis, by Mechanism of Action, 2023-2031
Figure 14: Global Cancer Cachexia Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 15: Global Cancer Cachexia Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 16: Global Cancer Cachexia Market Value Share Analysis, by Region, 2023 and 2031
Figure 17: Global Cancer Cachexia Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Cancer Cachexia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2022–2031
Figure 19: North America Cancer Cachexia Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Cancer Cachexia Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Cancer Cachexia Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 22: North America Cancer Cachexia Market Value Share Analysis, by Mechanism of Action, 2022 and 2031
Figure 23: North America Cancer Cachexia Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 24: North America Cancer Cachexia Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 25: North America Cancer Cachexia Market Attractiveness Analysis, by Mechanism of Action, 2023–2031
Figure 26:North America Cancer Cachexia Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Cancer Cachexia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2022–2031
Figure 28: Europe Cancer Cachexia Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Cancer Cachexia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Cancer Cachexia Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 31: Europe Cancer Cachexia Market Value Share Analysis, by Mechanism of Action, 2022 and 2031
Figure 32: Europe Cancer Cachexia Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Europe Cancer Cachexia Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 34: Europe Cancer Cachexia Market Attractiveness Analysis, by Mechanism of Action, 2023–2031
Figure 35: Europe Cancer Cachexia Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Cancer Cachexia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2022–2031
Figure 37: Asia Pacific Cancer Cachexia Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Cancer Cachexia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Cancer Cachexia Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 40: Asia Pacific Cancer Cachexia Market Value Share Analysis, by Mechanism of Action, 2022 and 2031
Figure 41: Asia Pacific Cancer Cachexia Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42: Asia Pacific Cancer Cachexia Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 43: Asia Pacific Cancer Cachexia Market Attractiveness Analysis, by Mechanism of Action, 2023–2031
Figure 44: Asia Pacific Cancer Cachexia Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Cancer Cachexia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2022–2031
Figure 46: Latin America Cancer Cachexia Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Cancer Cachexia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Cancer Cachexia Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 49: Latin America Cancer Cachexia Market Value Share Analysis, by Mechanism of Action, 2022 and 2031
Figure 50: Latin America Cancer Cachexia Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Latin America Cancer Cachexia Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 52: Latin America Cancer Cachexia Market Attractiveness Analysis, by Mechanism of Action, 2023–2031
Figure 53: Latin America Cancer Cachexia Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Cancer Cachexia Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2022–2031
Figure 55: Middle East & Africa Cancer Cachexia Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Cancer Cachexia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Cancer Cachexia Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 58: Middle East & Africa Cancer Cachexia Market Value Share Analysis, by Mechanism of Action, 2022 and 2031
Figure 59: Middle East & Africa Cancer Cachexia Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Middle East & Africa Cancer Cachexia Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 61: Middle East & Africa Cancer Cachexia Market Attractiveness Analysis, by Mechanism of Action, 2023–2031
Figure 62: Middle East & Africa Cancer Cachexia Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cancer Cachexia Market
*86 figures and 60 tables includes